Related Experiment Videos
Amikacin in gram-negative paediatric infections
Insights
Amikacin effectively treated Gram-negative infections in children, showing high cure rates across various infection sites. This study highlights amikacin
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Therapy
- Gram-Negative Infections
Background:
- Gram-negative bacterial infections pose significant risks in pediatric populations.
- Effective and safe antimicrobial agents are crucial for treating severe pediatric infections.
Purpose of the Study:
- To evaluate the efficacy and safety of amikacin in treating Gram-negative infections in children.
- To determine cure rates for amikacin therapy across different infection sites.
Main Methods:
- A study involving sixty-six children aged two days to thirteen years.
- Treatment with amikacin for various Gram-negative infections, including severe and moderate cases.
- Assessment of clinical and bacteriological cure rates post-treatment.
Main Results:
- Amikacin achieved a high overall cure rate of 92% (82% complete, 10% partial) in sixty-six pediatric patients.
- Excellent efficacy was observed in urinary/gastro-intestinal (95% cure) and skin/soft tissue infections (94% cure).
- A 75% cure rate was noted for respiratory tract infections.
Conclusions:
- Amikacin demonstrates significant efficacy in treating a broad spectrum of Gram-negative bacterial infections in children.
- The drug is a valuable therapeutic option for severe pediatric infections, with favorable outcomes across multiple infection sites.
- High cure rates support the continued use of amikacin in pediatric infectious disease management.
Abstract:
Amikacin was used in the treatment of various Gram-negative infections in sixty-six children ranging in age from two days to thirteen years. Over 72% of the infections treated were classified as severe and the remainder were moderate. Among infections in which the site of origin was the urinary or gastro-intestinal tract, amikacin achieved thirty-eight (95%) complete or partial cures in forty patients. In respiratory tract infections, amikacin completely or partially cured six (75%) out of eight patients. The remaining eighteen infections involved skin, soft tissue and other miscellaneous categories in which amikacin therapy resulted in seventeen (94%) complete or partial cures. Overall, amikacin achieved fifty-four complete cures and seven clinical or bacteriological cures in sixty-six patients, which represents an 82% complete cure rate and 10% partial cure rate for all the patients in the study.